Quote:

---

i'm wondering if a PR about injecting the first patient in Brazil gives our SP a boost?

on the one hand, it's great news - and shows that the trial is on track. on the other hand, longs all assume the trial will proceed - so it actually proceeding may or may not already be priced in.

---

IMO it will give the share price a significant boost. Many people were starting to worry that the Brazil trial would go away like news from Mexico or Canada, etc. and that includes some diehard longs.

Many of us were extremely confident in CD12. It seemed like a no-brainer. However we didn’t know about the imbalance in the age groups, and we also trusted DSMC — both of which absolutely screwed the outcome. Based on what we learned from the trial, we can now be more certain than ever that CD15 and CD16 will crush the primary endpoint.

So if Brazil goes forward we will prove that the Leronlimab works for Covid and get an approval and revenue. If the trial does not go forward, I doubt LL will ever be used for critical and severe Covid.

Yes, trial moving forward will lift the share price. It will mean approval is months away.